A Pilot Study of the Effectiveness and Safety of Subcutaneous Infliximab in Chronic Inflammatory Pouch Conditions: The St. Mark’s Experience

Key Takeaways for GI Nurses

• Subcutaneous infliximab represents a potential paradigm shift from traditional IV infusion therapy for inflammatory pouch conditions, offering more convenient outpatient administration options
• This pilot study provides preliminary evidence for expanding treatment modalities beyond standard pouchitis management protocols currently used in most endoscopy units
• The subcutaneous route may reduce infusion center burden and allow for patient self-administration, significantly impacting unit scheduling and resource allocation
• Safety monitoring protocols will need adaptation as patients transition from supervised IV infusions to subcutaneous injections with different adverse event profiles

Clinical Relevance

This pilot study has significant implications for gastroenterology nursing practice, particularly in units managing patients with ileal pouch-anal anastomosis (IPAA) complications. Traditional management of chronic inflammatory pouch conditions has relied heavily on IV biologics administered in infusion centers, requiring substantial nursing resources, dedicated infusion chairs, and extended patient monitoring periods. The potential effectiveness of subcutaneous infliximab could fundamentally alter workflow patterns and resource utilization in GI units.

From a patient care perspective, subcutaneous administration offers enhanced convenience and improved quality of life for patients managing chronic pouch inflammation. GI nurses will need to develop new competencies in subcutaneous injection education, monitoring for injection site reactions, and modified assessment protocols that account for the different pharmacokinetic profiles of subcutaneous versus intravenous biologics. This transition also necessitates updated patient education materials and discharge planning processes to ensure safe home administration.

The operational impact extends beyond direct patient care to include inventory management, insurance authorization processes, and coordination with specialty pharmacies for home delivery of subcutaneous formulations. Nurses will play a crucial role in identifying appropriate candidates for this therapy transition and monitoring treatment responses through both clinical assessments and endoscopic evaluations during routine surveillance procedures.

Bottom Line

While still in pilot phase, subcutaneous infliximab for chronic inflammatory pouch conditions represents a promising advancement that could transform how GI nurses deliver biologic therapy, shifting from resource-intensive infusion center models to more flexible outpatient management strategies that improve patient convenience while maintaining therapeutic effectiveness and safety standards.